Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.

PubWeight™: 1.89‹?› | Rank: Top 3%

🔗 View Article (PMID 11423985)

Published in Oncogene on June 07, 2001

Authors

C B Umbricht1, E Evron, E Gabrielson, A Ferguson, J Marks, S Sukumar

Author Affiliations

1: Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, MD 21231, USA.

Articles citing this

The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol (2008) 3.30

Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12

The p53 pathway in breast cancer. Breast Cancer Res (2002) 1.94

Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71

Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol (2002) 1.68

Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res (2009) 1.65

Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol (2002) 1.53

Genetic alteration and gene expression modulation during cancer progression. Mol Cancer (2004) 1.50

Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch (2010) 1.34

Epigenomics and breast cancer. Pharmacogenomics (2008) 1.23

MSRE-PCR for analysis of gene-specific DNA methylation. Nucleic Acids Res (2005) 1.21

Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res (2010) 1.18

DNA methylation as a universal biomarker. Expert Rev Mol Diagn (2010) 1.18

CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol (2007) 1.16

An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res (2011) 1.13

Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem (2009) 1.12

Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer (2008) 1.11

Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clin Exp Metastasis (2008) 1.10

Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn (2007) 1.07

14-3-3sigma, the double-edged sword of human cancers. Am J Transl Res (2009) 1.07

Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res (2009) 1.06

Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer (2010) 1.05

Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol (2002) 1.05

Local regulation of human breast xenograft models. J Cell Physiol (2010) 1.04

Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci (2015) 1.04

Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res (2005) 1.03

Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers. BMC Cancer (2010) 1.01

Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol (2007) 0.99

Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer (2010) 0.99

DNA methylation as clinically useful biomarkers-light at the end of the tunnel. Pharmaceuticals (Basel) (2012) 0.99

Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids. Int J Cancer (2010) 0.95

DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer (2008) 0.94

CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer (2011) 0.93

14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence. Mol Cancer (2009) 0.92

Epigenetic regulation of the cell type-specific gene 14-3-3sigma. Neoplasia (2005) 0.92

Breast cancer proteomics: a review for clinicians. J Cancer Res Clin Oncol (2011) 0.91

Do we use the appropriate controls for the identification of informative methylation markers for early cancer detection? Genome Biol (2008) 0.91

Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer (2011) 0.90

Aberrant promoter methylation and expression of the imprinted PEG3 gene in glioma. Proc Jpn Acad Ser B Phys Biol Sci (2009) 0.89

Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. Cancer Biomark (2009) 0.89

Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr Relat Cancer (2016) 0.88

Hypomethylation of the 14-3-3σ promoter leads to increased expression in non-small cell lung cancer. Genes Chromosomes Cancer (2011) 0.87

Toward an orofacial gene regulatory network. Dev Dyn (2015) 0.85

Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors. Mol Cancer (2007) 0.85

Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol (2009) 0.85

Downregulation of 14-3-3σ correlates with multistage carcinogenesis and poor prognosis of esophageal squamous cell carcinoma. PLoS One (2014) 0.84

Reduced ING1 levels in breast cancer promotes metastasis. Oncotarget (2014) 0.82

DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res (2013) 0.81

Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Dig Dis Sci (2010) 0.80

Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival. FASEB J (2008) 0.80

Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News Perspect (2009) 0.80

Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis. Oncotarget (2017) 0.79

Application of DNA methylation biomarkers for endometrial cancer management. Expert Rev Mol Diagn (2008) 0.79

The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation. Cancer Biol Ther (2012) 0.78

The 14-3-3sigma gene promoter is methylated in both human melanocytes and melanoma. BMC Cancer (2009) 0.78

Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis. Virol J (2014) 0.77

Toxoplasma gondii: effect of infection on expression of 14-3-3 proteins in human epithelial cells. Exp Parasitol (2007) 0.77

Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer. Breast Cancer (Auckl) (2016) 0.77

P53 suppresses expression of the 14-3-3 gamma oncogene. BMC Cancer (2011) 0.77

14-3-3τ promotes breast cancer invasion and metastasis by inhibiting RhoGDIα. Mol Cell Biol (2014) 0.76

Deletion of 14-3-3σ sensitizes mice to DMBA/TPA-induced papillomatosis. Oncotarget (2016) 0.75

Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies. BMC Cancer (2007) 0.75

The role and regulatory mechanism of 14-3-3 sigma in human breast cancer. J Breast Cancer (2014) 0.75

Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma. Oncotarget (2017) 0.75

Articles by these authors

5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA (1997) 8.30

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38

Quantitation of intraepithelial lymphocytes in human jejunum. Gut (1971) 6.18

Frequency of "functional" gastrointestinal disorders. Lancet (1977) 5.73

Small-bowel changes in dermatitis herpetiformis. Lancet (1966) 4.49

Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature (1985) 4.40

Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature (1984) 4.38

Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80

Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature (2000) 3.78

Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76

Similarities in intestinal humoral immunity in dermatitis herpetiformis without enteropathy and in coeliac disease. Lancet (1990) 3.37

Intraepithelial lymphocytes of the small intestine. Gut (1977) 3.21

HLA-DQ and T-cell receptor genes in insulin-dependent diabetes mellitus. Cold Spring Harb Symp Quant Biol (1986) 3.15

The effect of antigen deprivation on thymus-dependent and thymus-independent lymphocytes in the small intestine of the mouse. Clin Exp Immunol (1972) 3.09

Selective migration of lymphocytes within the mouse small intestine. Immunology (1974) 3.06

A critical review of adaptive genetic variation in Atlantic salmon: implications for conservation. Biol Rev Camb Philos Soc (2007) 2.98

Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97

Changes in clinical features of coeliac disease in adults in Edinburgh and the Lothians 1960-79. Br Med J (Clin Res Ed) (1983) 2.91

Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology (1993) 2.79

Coeliac syndrome in dermatitis herpetiformis. Lancet (1968) 2.73

High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70

Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology (1998) 2.68

Ending the routine guinea-pig test. Tubercle (1972) 2.56

Immunological responses to fed protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide. Immunology (1982) 2.50

Intestinal inflammation in cystic fibrosis. Arch Dis Child (2000) 2.46

Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology (1994) 2.45

Too many patients, too few cardiologists to care? Can J Cardiol (2006) 2.45

Molecular links between obesity and breast cancer. Endocr Relat Cancer (2006) 2.44

The effects of different component response requirements in multiple and concurrent schedules. J Exp Anal Behav (1978) 2.43

HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene (2011) 2.42

Cell-mediated immunity to gliadin within the small-intestinal mucosa in coeliac disease. Lancet (1975) 2.41

Prevalence and "incidence" of celiac disease in Edinburgh and the Lothian region of Scotland. Gastroenterology (1986) 2.34

High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol (2002) 2.33

Intraepithelial cells in the human intestinal mucosa. J Ultrastruct Res (1971) 2.31

Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys (1995) 2.28

Precipitins to dietary proteins in serum and upper intestinal secretions of coeliac children. Br Med J (1972) 2.25

Mortality in celiac disease. Gastroenterology (1989) 2.24

Failure to record variables of growth and development in children with inflammatory bowel disease. BMJ (1989) 2.22

Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18

RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev (1994) 2.17

Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 2.16

Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer (2008) 2.13

Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis (2005) 2.11

Human intestinal mucosal mast cells: evaluation of fixation and staining techniques. J Clin Pathol (1981) 2.11

The clinical features of chronic vitamin deficiency. A therapeutic trial in geriatric hospital patients. Gerontol Clin (Basel) (1968) 2.09

Lymphocytes in Whipple's disease. Lancet (1968) 2.06

Hypersensitivity reactions in the small intestine. III. The effects of allograft rejection and of graft-versus-host disease on epithelial cell kinetics. Cell Tissue Kinet (1977) 2.00

A system for the examination of tubercle bacilli and other mycobacteria. Tubercle (1976) 2.00

Immunological responses to fed protein antigens in mice. II. Oral tolerance for CMI is due to activation of cyclophosphamide-sensitive cells by gut-processed antigen. Immunology (1983) 1.99

Purpura associated with vomiting in pregnancy. Br Med J (1973) 1.98

Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation. Fertil Steril (1989) 1.98

Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res (2001) 1.98

Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res (2001) 1.95

Intraepithelial lymphocyte count and crypt hyperplasia measure the mucosal component of the graft-versus-host reaction in mouse small intestine. Gastroenterology (1982) 1.92

Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry (2004) 1.92

Hypersensitivity in the small intestinal mucosa. V. Induction of cell-mediated immunity to a dietary antigen. Clin Exp Immunol (1981) 1.91

Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet (1979) 1.87

A randomized controlled study on the effectiveness of a multifaceted intervention program in the primary prevention of asthma in high-risk infants. Arch Pediatr Adolesc Med (2000) 1.85

Doublet discrimination in DNA cell-cycle analysis. Cytometry (2001) 1.83

Gastrointestinal amyloidosis in psoriatic arthritis. Ann Rheum Dis (1968) 1.81

Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res (1998) 1.81

Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res (1996) 1.80

The S. pombe cdc16 gene is required both for maintenance of p34cdc2 kinase activity and regulation of septum formation: a link between mitosis and cytokinesis? EMBO J (1993) 1.80

Reduction of gastrointestinal protein loss by elemental diet in Crohn's disease of the small bowel. Gut (1981) 1.77

Cell kinetics in flat (avillous) mucosa of the human small intestine. Gut (1973) 1.76

Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res (1999) 1.74

Hypersensitivity reactions in small intestine. I Thymus dependence of experimental 'partial villous atrophy'. Gut (1975) 1.74

Opium, the religion of the people. Lancet (1985) 1.74

Intraepithelial lymphocyte counts in small intestinal biopsies from children with diarrhoea. Acta Paediatr Scand (1976) 1.73

Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res (2001) 1.73

Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res (1998) 1.71

Primary biliary cirrhosis and coeliac disease: an association? Lancet (1978) 1.70

Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res (1999) 1.69

Growth and development of "antigen-free" grafts of foetal mouse intestine. J Pathol (1972) 1.68

Activation of ras oncogenes preceding the onset of neoplasia. Science (1990) 1.68

Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut (1999) 1.67

Small intestine in psoriasis. Br Med J (1967) 1.66

Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci U S A (1991) 1.65

Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three-fold rise in Crohn's disease. Gut (1989) 1.64

Genetic divergence in the clonal evolution of breast cancer. Cancer Res (1996) 1.63

Adult coeliac disease in hyposplenic patients. Lancet (1970) 1.63

Hypersensitivity reactions in the small intestine. 2. Effects of allograft rejection on mucosal architecture and lymphoid cell infiltrate. Gut (1976) 1.62

Lipid chromatography and seroagglutination in the classification of rapidly growing mycobacteria. Am Rev Respir Dis (1971) 1.62

Siderophore presence in sputa of cystic fibrosis patients. Infect Immun (1991) 1.61

Dissociation between systemic and mucosal humoral immune responses in coeliac disease. Gut (1991) 1.61

Intestinal antibody pattern of celiac disease: occurrence in patients with normal jejunal biopsy histology. Gastroenterology (1993) 1.61

Classification of Mycobacterium avium and related opportunist mycobacteria met in England and Wales. J Hyg (Lond) (1967) 1.61

Immune responses to fed protein antigens in mice. 3. Systemic tolerance or priming is related to age at which antigen is first encountered. Pediatr Res (1984) 1.60

Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. Lancet (1995) 1.59

Clinical features, morbidity and mortality of Scottish children with inflammatory bowel disease. Q J Med (1990) 1.56

Improving the standard of operation notes in orthopaedic and trauma surgery: the value of a proforma. Injury (2004) 1.54

Hypersensitivity reactions in the small intestine. 6. Pathogenesis of the graft-versus-host reaction in the small intestinal mucosa of the mouse. Transplantation (1981) 1.54

Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya. Sex Transm Infect (2006) 1.53